Key result
Continuous Angiotensin II reveals multiple cell populations driving pathological extracellular matrix remodeling.
Why the study?
The specific cellular and molecular mediators driving cardiac fibrosis, and the relative impact of disparate cell populations, remained unclear.
Provides a high-resolution single-cell transcriptomic map of the heart under chronic stress, revealing novel fibroblast populations and sexually dimorphic responses that drive early pathological remodeling.
Background Cardiac fibrosis is a key antecedent to many types of cardiac dysfunction including heart failure. Physiological factors leading to cardiac fibrosis have been recognized for decades. However, the specific cellular and molecular mediators that drive cardiac fibrosis, and the relative impact of disparate cell populations on cardiac fibrosis, remain unclear. Methods We developed a novel cardiac single-cell transcriptomics strategy to characterize the cardiac cellulome—the network of cells that forms the heart. This method was utilized to profile the cardiac cellular ecosystem in response to two weeks of continuous administration of Angiotensin II, a pro-fibrotic stimulus which drives pathological cardiac remodeling. Results This analysis uncovered multiple cell populations contributing to pathological remodeling of the extracellular matrix of the heart. Two phenotypically distinct fibroblast populations emerged after induction of tissue stress to promote fibrosis in the absence of smooth muscle actin-expressing myofibroblasts, a key pro-fibrotic cell population. Further, the cellular responses to Angiotensin II and the relative abundance of fibrogenic cells were sexually dimorphic. Conclusions These results offer a valuable resource for exploring the cardiac cellular landscape in health and after chronic cardiovascular stress. These data provide insights into the cellular and molecular mechanisms that promote pathological remodeling of the mammalian heart, highlighting early transcriptional changes which precede chronic cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
McLellan et al. (2019) studied Cardiac fibrosis and hypertrophy. Angiotensin II was evaluated on Cellular and molecular mediators driving cardiac fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: